|
|
|
Two short videos explaining what you need to know about VELCADE SQ. |
|
|
|
|
|
|
![]()
|
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.
|
|
|
|
|
|
Two months ago, I started on VELCADE subcutaneous. It’s just a shot. I don’t
have to wait for an IV. It’s just in-and-out. VELCADE has kept me going and
feeling well enough to live my life. |
|
|
|
|
|
The US Food and Drug Administration (FDA) has approved subcutaneous VELCADE for the treatment of multiple myeloma. This approval was based on a large, international clinical trial that studied VELCADE injected under the skin compared with VELCADE injected into a vein. The 222 patients in this study had been treated for their myeloma and relapsed. |
|
|
|
|
|
Information for patients and clinicans on indications and usage. |
|
|
|
|
|
back
print
back to top